{"id":71409,"date":"2026-05-20T09:18:16","date_gmt":"2026-05-20T09:18:16","guid":{"rendered":"https:\/\/medsbase.com\/l-carnitine\/"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"l-carnitine","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fr\/product\/l-carnitine\/","title":{"rendered":"L-Carnitine (Levocarnitine)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">R\u00e9ponse rapide \u2014 Qu'est-ce que la L-Carnitine ?<\/h3>\n<p style=\"margin: 0;\"><strong>L-Carnitine<\/strong> (levocarnitine ; (3R)-3-hydroxy-4-(trim\u00e9thylammonio)butanoate) est un petit d\u00e9riv\u00e9 d'acide amin\u00e9 \u00e0 ammonium quaternaire \u2014 <em>pas un peptide<\/em> \u2014 that functions as the essential carrier molecule for transporting long-chain fatty acids across the mitochondrial inner membrane for \u03b2-oxidation. It is endogenously biosynthesised from L-lysine and L-methionine and is concentrated in skeletal muscle, heart, and liver. L-Carnitine is studied across mitochondrial-function studies, fat-oxidation physiology, insulin-sensitivity models, cardiovascular studies, neuroprotection (Alzheimer \/ autism in-vitro work), exercise physiology, and sperm-motility studies. Supplied in 600 mg and 1200 mg vials as levocarnitine USP-grade zwitterion for clinical studies use only. Stocked in our peptide catalogue alongside <a href=\"https:\/\/medsbase.com\/fr\/nad\/\">NAD\u207a<\/a> as a complementary mitochondrial \/ metabolic support-injectable.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce que vous obtenez avec MedsBase :<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/fr\/reviews\/\">avis clients<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Chaque commande est couverte par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\"><strong>Politique de R\u00e9exp\u00e9ditions Garanties<\/strong><\/a> \u2014 si votre colis n'arrive pas dans les 20 jours ouvrables, nous le r\u00e9exp\u00e9dions.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Sp\u00e9cification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">D\u00e9tail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u00e9ro CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">541-15-1 (sel interne de L-carnitine \/ zwitterion)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Type<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">D\u00e9riv\u00e9 d'acide amin\u00e9 \u00e0 ammonium quaternaire (<em>pas un peptide<\/em>); l'\u00e9nantiom\u00e8re l\u00e9vorotatoire (3R) est la forme biologiquement active responsable du transport des acides gras \u00e0 longue cha\u00eene dans les mitochondries via le syst\u00e8me carnitine palmitoyltransf\u00e9rase (CPT-I \/ CPT-II); biosynth\u00e9tis\u00e9 de mani\u00e8re endog\u00e8ne \u00e0 partir de la L-lysine et de la L-m\u00e9thionine; \u00e9galement appel\u00e9 levocarnitine (DCI) ou vitamine B<sub>T<\/sub> dans les anciennes publications<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formule mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>7<\/sub>H<sub>15<\/sub>NON<sub>3<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">161,20 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nom IUPAC<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">(3R)-3-Hydroxy-4-(trim\u00e9thylazaniumyl)butanoate<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>S\u00e9quence<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">n\/a (petite mol\u00e9cule d\u00e9riv\u00e9e d'acide amin\u00e9 \u2014 pas un peptide)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Poudre lyophilis\u00e9e, blanche \u00e0 blanc cass\u00e9 (forme zwitterion \/ sel interne)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puret\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599 % (v\u00e9rifi\u00e9 par HPLC, COA sur demande)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Stockage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilis\u00e9 : 2\u20138 \u00b0C (r\u00e9frig\u00e9rateur) pour le stock de travail \u00e0 court terme ; \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Reconstitu\u00e9 : 2\u20138 \u00b0C, \u00e0 utiliser dans les ~30 jours. Prot\u00e9ger de la lumi\u00e8re. \u00c9viter les cycles r\u00e9p\u00e9t\u00e9s de cong\u00e9lation-d\u00e9cong\u00e9lation de la solution reconstitu\u00e9e. La levocarnitine est hygroscopique \u2014 refermer les flacons rapidement apr\u00e8s chaque pr\u00e9l\u00e8vement.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tr\u00e8s soluble dans l'eau (zwitterion \u00e0 pH physiologique). Se reconstitue rapidement dans de l'eau bact\u00e9riostatique ou de l'eau st\u00e9rile avec un l\u00e9ger mouvement circulaire. Aucun solvant sp\u00e9cialis\u00e9 requis. Des solutions de travail peuvent \u00eatre pr\u00e9par\u00e9es \u00e0 des concentrations allant jusqu'\u00e0 ~500 mg\/mL sans pr\u00e9cipitation.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Qu'est-ce que la L-Carnitine ?<\/h2>\n<p><strong>L-Carnitine<\/strong> (l\u00e9vocarnitine) est un petit d\u00e9riv\u00e9 d'acide amin\u00e9 quaternaire-ammonium hydrosoluble de formule mol\u00e9culaire C<sub>7<\/sub>H<sub>15<\/sub>NON<sub>3<\/sub> et de poids mol\u00e9culaire 161,20 g\/mol. Elle est <em>pas un peptide<\/em> \u2014 it is a single-residue zwitterionic molecule derived metabolically from the amino acids L-lysine and L-methionine through a multistep biosynthetic pathway distributed across kidney, liver, and brain. Only the (3R) enantiomer (the L-form \/ levo form \/ levocarnitine) is biologically active; the (3S) enantiomer (D-carnitine) is inactive and is now well-documented to interfere with the L-form&#8217;s transport, which is why pharmaceutical-grade material is supplied as the enantiomerically pure L-form rather than as racemic DL-carnitine. The molecule&#8217;s central physiological function is to serve as the <strong>transporteur obligatoire<\/strong> pour le transport des acides gras \u00e0 longue cha\u00eene (C<sub>12<\/sub>+) across the otherwise-impermeable mitochondrial inner membrane, where they are subsequently broken down by \u03b2-oxidation to acetyl-CoA, the substrate for the citric acid cycle and ATP synthesis. The transport machinery \u2014 carnitine palmitoyltransferase I (CPT-I) on the outer mitochondrial membrane, the carnitine\/acylcarnitine translocase (CACT) across the inner membrane, and carnitine palmitoyltransferase II (CPT-II) on the matrix side \u2014 converts free fatty acids into acylcarnitines, ferries them across the bilayer, and releases them again as acyl-CoAs for oxidation. L-Carnitine is therefore the rate-limiting metabolite for fat oxidation in tissues with high oxidative demand: skeletal muscle, cardiac muscle, and liver. L-Carnitine is also a high-affinity buffer of the cellular acyl-CoA \/ free-CoA ratio. By accepting acyl groups onto its hydroxyl side chain, L-carnitine maintains the intracellular pool of free CoA that other CoA-dependent enzymes (pyruvate dehydrogenase, \u03b1-ketoglutarate dehydrogenase, fatty-acid \u03b2-oxidation) require to function. Carnitine deficiency therefore produces effects beyond fat oxidation alone \u2014 propagating into pyruvate handling, TCA-cycle flux, and overall mitochondrial bioenergetic balance. L-Carnitine has FDA approval (under the name <em>levocarnitine<\/em>) pour un usage th\u00e9rapeutique humain dans les cas de <strong>carence primaire et secondaire en carnitine<\/strong> (oral and IV formulations) and is widely used in contexts that examine mitochondrial bioenergetics, fat oxidation, insulin sensitivity, cardiovascular function, neuroprotection, exercise physiology, and sperm motility. <\/p>\n<h2>M\u00e9canisme d'action \u2014 Transport mitochondrial des acides gras \u00e0 longue cha\u00eene<\/h2>\n<p>L-Carnitine&#8217;s central mechanism is documented across several decades of mitochondrial biochemistry studies:<\/p>\n<ul>\n<li><strong>Carnitine palmitoyltransf\u00e9rase I (CPT-I) \u2014 membrane mitochondriale externe<\/strong> \u2014 Les acides gras \u00e0 longue cha\u00eene s'activent d'abord en acyl-CoA \u00e0 longue cha\u00eene dans le cytoplasme. La CPT-I, int\u00e9gr\u00e9e dans la membrane mitochondriale externe, transf\u00e8re le groupe acyl du CoA sur l'hydroxyle de la L-carnitine, g\u00e9n\u00e9rant ainsi l'acylcarnitine \u00e0 longue cha\u00eene. Il s'agit de l'\u00e9tape engag\u00e9e et la plus r\u00e9gul\u00e9e de l'oxydation mitochondriale des graisses \u2014 la CPT-I est inhib\u00e9e allost\u00e9riquement par le malonyl-CoA (le produit de l'ac\u00e9tyl-CoA carboxylase dans le m\u00e9tabolisme lipog\u00e9nique en \u00e9tat nourri), ce qui explique comment l'insuline \/ le glucagon et le syst\u00e8me AMPK r\u00e9gulent l'oxydation des graisses par rapport \u00e0 la synth\u00e8se des graisses.<\/li>\n<li><strong>Carnitine\/acylcarnitine translocase (CACT) \u2014 membrane mitochondriale interne<\/strong> \u2014 L'acylcarnitine \u00e0 longue cha\u00eene g\u00e9n\u00e9r\u00e9e par la CPT-I ne peut pas diffuser \u00e0 travers la membrane mitochondriale interne. La CACT, un antiporteur, \u00e9change l'acylcarnitine cytosolique contre la carnitine libre de la matrice dans une st\u0153chiom\u00e9trie 1:1, livrant ainsi l'acylcarnitine dans la matrice et recyclant la carnitine pour d'autres cycles de CPT-I.<\/li>\n<li><strong>Carnitine palmitoyltransf\u00e9rase II (CPT-II) \u2014 membrane mitochondriale interne, c\u00f4t\u00e9 matrice<\/strong> \u2014 Dans la matrice, la CPT-II inverse la r\u00e9action de la CPT-I : elle transf\u00e8re le groupe acyl de la carnitine vers le CoA de la matrice, r\u00e9g\u00e9n\u00e9rant ainsi l'acyl-CoA \u00e0 longue cha\u00eene, qui peut maintenant entrer dans la \u03b2-oxydation. La carnitine libre lib\u00e9r\u00e9e est renvoy\u00e9e \u00e0 travers la membrane via la CACT pour un autre cycle de transport.<\/li>\n<li><strong>Tamponnement du rapport acyl-CoA \/ CoA libre et flexibilit\u00e9 m\u00e9tabolique<\/strong> \u2014 Au-del\u00e0 de la navette des acides gras \u00e0 longue cha\u00eene, la L-carnitine accepte les groupes acyl \u00e0 cha\u00eene courte et moyenne (ac\u00e9tylcarnitine, propionylcarnitine) et agit comme un tampon \u00e0 haute capacit\u00e9 du rapport intracellulaire acyl-CoA \/ CoA libre. Cela maintient le CoA libre pour la pyruvate d\u00e9shydrog\u00e9nase, l'\u03b1-c\u00e9toglutarate d\u00e9shydrog\u00e9nase et la \u03b2-oxydation. La g\u00e9n\u00e9ration d'ac\u00e9tylcarnitine sert \u00e9galement de m\u00e9canisme par lequel l'exc\u00e8s d'ac\u00e9tyl-CoA \u2014 provenant du je\u00fbne, de la c\u00e9togen\u00e8se, de l'exercice \u2014 peut \u00eatre tamponn\u00e9 en toute s\u00e9curit\u00e9 et export\u00e9 \u00e0 travers la membrane mitochondriale.<\/li>\n<\/ul>\n<p>The pharmacokinetic profile of orally-administered L-carnitine is unusual: oral bioavailability is low (~15%) due to active intestinal saturation, with the remaining 85% subject to extensive bacterial degradation in the colon (yielding TMA and TMAO \u2014 a finding that has attracted attention in cardiovascular studies). Intravenous and intramuscular administration routes achieve much higher plasma levels and bypass the gut-microbial degradation pathway entirely, which is why pharmacological protocols commonly use parenteral administration despite the convenience of oral dosing. <\/p>\n<h2>Published Evidence<\/h2>\n<p>L-Carnitine is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>La fonction mitochondriale et la bio\u00e9nerg\u00e9tique<\/strong> \u2014 Respirom\u00e9trie Seahorse \/ Oroboros, potentiel de membrane mitochondriale, taux de g\u00e9n\u00e9ration d'ATP, taux d'oxydation des acides gras dans les cultures d'h\u00e9patocytes primaires, de muscle squelettique et de cardiomyocytes<\/li>\n<li><strong>L'oxydation des graisses et la flexibilit\u00e9 m\u00e9tabolique<\/strong> \u2014 Passage entre l'oxydation du glucose et des graisses dans le muscle squelettique et le foie ; mod\u00e8les de r\u00e9version de la r\u00e9sistance \u00e0 l'insuline ; cohortes d'\u00e9tudes sur les rongeurs ob\u00e8ses et le DIO<\/li>\n<li><strong>Insulin sensitivity studies<\/strong> \u2014 improvement in skeletal-muscle insulin sensitivity in models of metabolic syndrome and type 2 diabetes preclinical studies; mechanistic dissection of the L-carnitine \/ acyl-CoA buffering \/ pyruvate handling axis<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 angina, heart failure, ischemia-reperfusion injury, cardiomyopathy (in particular doxorubicin-induced cardiotoxicity and primary carnitine-deficiency cardiomyopathy); TMA\/TMAO microbiome-axis cardiovascular studies<\/li>\n<li><strong>Neuroprotection studies<\/strong> \u2014 Alzheimer-disease in-vitro models (acetylcarnitine specifically), Parkinson-disease models, peripheral diabetic neuropathy preclinical models, autism-spectrum studies where carnitine deficiency has been implicated<\/li>\n<li><strong>Sperm motility and male fertility studies<\/strong> \u2014 epididymal acquisition of motility, mitochondrial energetics of sperm flagellar beat, antioxidant protection of spermatozoa; one of the most-studied compounds in male-fertility studies<\/li>\n<li><strong>Exercise physiology and endurance studies<\/strong> \u2014 substrate utilisation during prolonged exercise, glycogen sparing, post-exercise recovery; studies interest in carnitine loading protocols and insulin co-administration to overcome muscle-uptake saturation<\/li>\n<li><strong>Chronic kidney disease \/ haemodialysis studies<\/strong> \u2014 carnitine deficiency is common in dialysis-dependent end-stage renal disease patients and L-carnitine has FDA approval for this indication; preclinical studies continues on dialysis-related cardiomyopathy and muscle weakness<\/li>\n<\/ul>\n<p>For broader context on mitochondrial and metabolic-axis compounds in this catalogue, see <a href=\"https:\/\/medsbase.com\/fr\/nad\/\">NAD\u207a<\/a> (coenzyme dinucl\u00e9otide oxyd\u00e9, substrat central du transport d'\u00e9lectrons), <a href=\"https:\/\/medsbase.com\/fr\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> (peptide ciblant les mitochondries et se liant \u00e0 la cardiolipine), et <a href=\"https:\/\/medsbase.com\/fr\/mots-c\/\">MOTS-c<\/a> (peptide r\u00e9gulateur m\u00e9tabolique d'origine mitochondriale). Parcourez l'int\u00e9gralit\u00e9 <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\">peptides &amp; compounds catalog<\/a> pour les compos\u00e9s associ\u00e9s. <\/p>\n<h2>Forces et concentrations disponibles<\/h2>\n<p>MedsBase stocks L-Carnitine in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Concentration du flacon<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cas d'utilisation typique<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tailles de conditionnement<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>600 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 dose-titration protocols, in-vitro mitochondrial-function panels, short-cycle in-vivo work, sperm-motility studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>1200 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle or higher-dose protocols \u2014 long-arm metabolic studies, exercise-physiology saturation experiments, multi-cohort work; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized levocarnitine zwitterion, \u226599% HPLC purity). Vial doses are deliberately much larger than the peptide range (5\u201320 mg) because L-carnitine is a small molecule used at gram-level doses \u2014 a 600 mg or 1200 mg vial corresponds roughly to a single intravenous dose in rodent or large-animal protocols. Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>Comparaison \u2014 L-Carnitine vs NAD\u207a<\/h2>\n<p>L-Carnitine et <a href=\"https:\/\/medsbase.com\/fr\/nad\/\">NAD\u207a<\/a> are the two non-peptide mitochondrial \/ metabolic support compounds in this catalogue, and they target completely different layers of mitochondrial bioenergetics. L-Carnitine sits on the <em>du carburant<\/em> \u2014 elle transporte les acides gras \u00e0 longue cha\u00eene dans la matrice pour la \u03b2-oxydation. Le NAD\u207a se situe du c\u00f4t\u00e9 <em>du transport d'\u00e9lectrons<\/em> \u2014 it is the obligate electron acceptor for \u03b2-oxidation, glycolysis, and the TCA cycle, regenerated by Complex I of the electron transport chain. The two compounds are mechanistically complementary, and protocols sometimes combine them to probe upstream-substrate vs downstream-electron-flux contributions to mitochondrial output. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e8re<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">L-Carnitine<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">NAD\u207a<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Classe chimique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">D\u00e9riv\u00e9 d'acide amin\u00e9 \u00e0 ammonium quaternaire (zwitterion unique)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Coenzyme dinucl\u00e9otide (ad\u00e9nine + nucl\u00e9otides de nicotinamide li\u00e9s par un diphosphate)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">161,20 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">663,43 g\/mol<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>R\u00f4le dans les mitochondries<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Transporteur \u2014 navette des acides gras \u00e0 longue cha\u00eene \u00e0 travers la membrane interne<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Accepteur d'\u00e9lectrons pour la \u03b2-oxydation, la glycolyse, le cycle de Krebs ; substrat pour les sirtuines et les PARPs<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best-studied studies focus<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Oxydation des graisses, sensibilit\u00e9 \u00e0 l'insuline, sant\u00e9 cardiovasculaire, motilit\u00e9 des spermatozo\u00efdes, physiologie de l'exercice<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Biologie des sirtuines, long\u00e9vit\u00e9, vieillissement cellulaire, r\u00e9gulation redox de l'axe NAD<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Approbation FDA<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Oui \u2014 l\u00e9vocarnitine, pour une carence primaire\/secondaire en carnitine (voie orale et IV)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">No \u2014 compound only<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Biosynth\u00e8se endog\u00e8ne<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u00c0 partir de L-lysine et L-m\u00e9thionine, dans les reins\/foie\/cerveau<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u00c0 partir de tryptophane (de novo) ou de nicotinamide\/niacine (voie de r\u00e9cup\u00e9ration)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Stabilit\u00e9 plasmatique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Stable \u2014 demi-vie de plusieurs heures<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Instable \u2014 demi-vie de quelques minutes en solution ; s'oxyde et se d\u00e9grade rapidement<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose typique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Des centaines de mg \u00e0 plusieurs grammes (dose unique dans les protocoles sur rongeurs\/grands animaux)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Des dizaines \u00e0 des centaines de mg (culture cellulaire : concentrations en \u00b5M)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on long-chain fatty-acid oxidation, cardiovascular metabolic function, insulin sensitivity, or sperm motility, L-Carnitine is the canonical reference compound. For studies focused on sirtuin biology, longevity-axis biochemistry, or NAD-dependent redox regulation, <a href=\"https:\/\/medsbase.com\/fr\/nad\/\">NAD\u207a<\/a> est l'outil plus cibl\u00e9. Voir \u00e9galement <a href=\"https:\/\/medsbase.com\/fr\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> for cardiolipin \/ inner-membrane-targeted mitochondrial studies and <a href=\"https:\/\/medsbase.com\/fr\/mots-c\/\">MOTS-c<\/a> for mitochondrial-derived peptide-signalling studies. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Besoin d'eau BAC ?<\/strong> La reconstitution de tout flacon lyophilis\u00e9 n\u00e9cessite de l'eau bact\u00e9riostatique st\u00e9rile. Associez ce produit \u00e0 notre <a href=\"\/fr\/bac-water\/\"><strong>Eau BAC (Eau bact\u00e9riostatique)<\/strong><\/a> \u2014 flacon multidose de 30 mL, pr\u00e9serv\u00e9 par 0,9 % d'alcool benzylique, qualit\u00e9 USP.<\/div>\n<h2>Stockage et reconstitution<\/h2>\n<p><strong>Avant la reconstitution :<\/strong> conserver les flacons lyophilis\u00e9s r\u00e9frig\u00e9r\u00e9s \u00e0 2\u20138 \u00b0C dans leur emballage d'origine pour le stock de travail \u00e0 court terme. Pour le stockage \u00e0 long terme, congeler les flacons non ouverts \u00e0 \u221220 \u00b0C. La L-Carnitine lyophilis\u00e9e est stable sous r\u00e9frig\u00e9ration jusqu'\u00e0 36 mois et \u00e0 \u221220 \u00b0C jusqu'\u00e0 60 mois \u2014 nettement plus stable que la plupart des peptides lyophilis\u00e9s car la structure de la petite mol\u00e9cule ne contient pas de liaisons amides ou de ponts disulfures \u00e0 hydrolyser. Le compos\u00e9 est cependant, <strong>hygroscopique<\/strong>, refermez donc les flacons imm\u00e9diatement apr\u00e8s chaque pr\u00e9l\u00e8vement et \u00e9vitez une exposition prolong\u00e9e \u00e0 l'humidit\u00e9 ambiante. <strong>Proc\u00e9dure de reconstitution :<\/strong> injectez de l'eau bact\u00e9riostatique le long de la paroi lat\u00e9rale du flacon (pas directement sur la poudre lyophilis\u00e9e). Pour un flacon de 600 mg, 3,0 mL d'eau bact\u00e9riostatique donnent une concentration de travail de 200 mg\/mL ; 1,2 mL donnent une solution m\u00e8re \u00e0 500 mg\/mL. Pour un flacon de 1200 mg, 6,0 mL donnent une solution de travail \u00e0 200 mg\/mL ; 2,4 mL donnent une solution m\u00e8re \u00e0 500 mg\/mL. La L-Carnitine se dissout tr\u00e8s rapidement avec un l\u00e9ger mouvement de rotation \u2014 g\u00e9n\u00e9ralement en 10 \u00e0 30 secondes \u2014 car c'est un petit zwitterion sans structure repli\u00e9e \u00e0 d\u00e9faire. Une fois reconstitu\u00e9e, conservez le flacon \u00e0 2\u20138 \u00b0C et utilisez-le dans les 30 jours. Prot\u00e9gez de la lumi\u00e8re. Jetez en cas de turbidit\u00e9, de particules ou de changement de couleur. <\/p>\n<h2>Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<h3>La L-Carnitine est-elle un peptide ?<\/h3>\n<p>Non. La L-Carnitine est un d\u00e9riv\u00e9 d'acide amin\u00e9 quaternaire d'ammonium de petite mol\u00e9cule (PM 161,20 g\/mol), <em>re\u00e7oit pas<\/em> a peptide. We stock it in our studies-peptide catalogue alongside <a href=\"https:\/\/medsbase.com\/fr\/nad\/\">NAD\u207a<\/a> because it serves a complementary role in mitochondrial \/ metabolic support and is supplied in the same injectable vial format. The spec table Sequence row is marked &#8220;n\/a&#8221; for this reason. <\/p>\n<h3>Quelle est la diff\u00e9rence entre la L-Carnitine et l'ac\u00e9tyl-L-carnitine (ALCAR) ?<\/h3>\n<p>Acetyl-L-carnitine is L-carnitine with an acetyl group esterified to the hydroxyl side chain. ALCAR crosses the blood-brain barrier more efficiently and is the form most commonly used in CNS-focused studies (Alzheimer-disease, peripheral neuropathy). The base L-carnitine zwitterion that we supply here is the form used in peripheral metabolic support (cardiovascular, skeletal muscle, sperm motility, dialysis-related deficiency). The two compounds interconvert metabolically through carnitine acetyltransferase. <\/p>\n<h3>Quelle est la diff\u00e9rence entre la L-Carnitine et le DL-carnitine rac\u00e9mique ?<\/h3>\n<p>Only the L (3R) enantiomer is biologically active. The D (3S) enantiomer is inactive and is now well-documented to interfere with L-form transport, accumulating in tissue and producing weakness and other adverse effects in long-term high-dose contexts. Pharmaceutical-grade levocarnitine (what we supply) is the enantiomerically pure L-form. The racemic DL-form is obsolete and is no longer used in either clinical or rigorous contexts. <\/p>\n<h3>Why is the dose so much larger than the peptide doses in this catalogue?<\/h3>\n<p>L-Carnitine is a small molecule (MW 161) and is used at gram-level doses \u2014 the body&#8217;s endogenous carnitine pool is approximately 25 g, concentrated in skeletal muscle. Study protocols typically use 100\u2013500 mg\/kg in rodent in-vivo work, which translates to hundreds of milligrams to grams per dose. Compare this to peptides (BPC-157, semaglutide, etc.) where typical doses are 100 \u00b5g to 5 mg per administration \u2014 three to four orders of magnitude smaller, reflecting the different molecular weights and the different receptor \/ mechanism scales. <\/p>\n<h3>What is the TMA \/ TMAO question I see in cardiovascular studies?<\/h3>\n<p>A subset of L-carnitine ingested orally is degraded by gut bacteria to trimethylamine (TMA), which the liver then oxidises to trimethylamine-N-oxide (TMAO). Elevated TMAO levels have been associated in epidemiological studies with adverse cardiovascular events, raising a controversy about whether long-term high-dose oral L-carnitine supplementation may be net-beneficial or net-harmful for cardiovascular endpoints. The question is active and unresolved. Parenteral L-carnitine bypasses the gut-microbial degradation pathway and is not subject to this concern. <\/p>\n<h3>What does CPT-I inhibition mean in metabolic support?<\/h3>\n<p>Carnitine palmitoyltransferase I (CPT-I) is the rate-limiting enzyme for mitochondrial long-chain fatty-acid uptake. Etomoxir is a classical CPT-I inhibitor used to block fat oxidation in study models; it is the pharmacological tool counterpart to the L-carnitine substrate. Study protocols sometimes combine L-carnitine supplementation (substrate side) with CPT-I inhibition (enzymatic side) to dissect substrate-limited vs enzyme-limited fat oxidation in different tissues and conditions. <\/p>\n<h3>Can I combine L-Carnitine with NAD\u207a in the same protocol?<\/h3>\n<p>Yes \u2014 the two compounds target different layers of mitochondrial bioenergetics (substrate transport vs electron transport), and combination is commonly used in studies that aims to probe upstream vs downstream limitations on mitochondrial output. They are chemically stable in solution together. Reconstitute each separately first to establish stability and concentration accuracy, then combine immediately before use rather than co-storing reconstituted vials. <\/p>\n<h3>What route of administration is used in published studies?<\/h3>\n<p>Intravenous and intramuscular routes are most common in pharmacological studies because they bypass the low (~15%) oral bioavailability and the gut-microbial TMA\/TMAO degradation pathway. Subcutaneous administration is used in some rodent protocols. Oral administration is used in pharmacokinetic and nutritional studies where the bioavailability question is itself the studies focus. <!-- medsbase-related-alts-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Navette mitochondriale des acides gras \u00e0 longue cha\u00eene (pas un peptide)<br \/>\n\u2705 Substrat du syst\u00e8me de transport CPT-I \/ CACT \/ CPT-II<br \/>\n\u2705 \u00c9tudi\u00e9 dans les mod\u00e8les d'oxydation des graisses, de sensibilit\u00e9 \u00e0 l'insuline et cardiovasculaires<br \/>\n\u2705 Acyl-CoA \/ free-CoA ratio buffer; sperm-motility studies<br \/>\n\u2705 Levocarnitine approuv\u00e9e par la FDA pour la carence en carnitine (voie orale et intraveineuse)<\/p>\n<p><strong>L-Carnitine<\/strong> contient de la l\u00e9vocarnitine synth\u00e9tique.<\/p>","protected":false},"featured_media":71414,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6472,6469,6470,6471],"class_list":["post-71409","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-amino-acid-derivative","product_tag-l-carnitine","product_tag-levocarnitine","product_tag-mitochondrial","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product\/71409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/comments?post=71409"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media\/71414"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media?parent=71409"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_brand?post=71409"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_cat?post=71409"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_tag?post=71409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}